Abstract
Introduction
Sorafenib improves progression-free survival in advanced clear-cell renal-cell carcinoma patients progressing to first-line therapy, as has been shown in the placebo-controlled international TARGET trial. The aim of this study is to report the results of the patients included in the Spanish centres in this trial.
Patients and methods
The records of the patients in the database of the TARGET trial have been reviewed. Data about progression-free survival, overall survival and toxicity have been collected in order to do this subpopulation analysis.
Results
A total of 15 patients have been included (sorafenib arm 7, placebo arm 8). A trend to an improved progression-free survival in the sorafenib arm has been observed period Toxicity in the sorafenib arm has been manageable.
Conclusion
The analysis of these 15 patients has shown efficacy and toxicity results that follow the trend observed for the overall international population.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zhang X, Yamashita M, Uetsuki H, Kakehi Y (2002) Angiogenesis in renal cell carcinoma. Evaluation of micro vessel density, vascular endothelial growth factor and matrix metalloproteinases. Int J Urol 9:509–514
Moreira IS, Fernandes PA, Ramos MJ (2007) Vascular endothelial growth factor inhibition. A critical review. Anticancer Agents Med Chem 7:223–245
Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109
Smith RA, Dumas J, Adnane L, Wilhelm SM (2005) Sorafenib (BAY 43-9006, NexavarTM), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407:597–612
Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965–972
Chang YS, Adnane J, Trail PA et al (2007) Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59:561–574
Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505–2512
Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced Clear-cell Renal-cell carcinoma. N Engl J Med 356:125–134
Panageas KS, Ben-Porat L, Dickler MN et al (2007) When you look matters: the effect of assessment schedule on progression free survival. J Natl Cancer Inst 99:428–432
Johnson JR, Williams G, Pazdur R (2003) End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404–1411
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bellmunt, J., González-Larriba, J.L., Climent, M.Á. et al. Sorafenib TARGET Trial results in Spanish patients. Clin Transl Oncol 9, 671–673 (2007). https://doi.org/10.1007/s12094-007-0120-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-007-0120-6